Novartis launches first-of-its-kind not-for-profit portfolio of medicines for symptomatic treatment of COVID-19 Read more
Orchard Therapeutics Announces Global License Agreements for Stable Cell Line Technology from GSK Read more
BioAegis Therapeutics Receives Approval to Proceed with Phase 2 Trial of its Gelsolin COVID-19 Treatment Read more
Sanofi and MD Anderson announce strategic collaboration to accelerate oncology research and development Read more
Fate Therapeutics Announces Exclusive License Agreement with Baylor College of Medicine for Rejection-resistant iPSC-derived Cellular Therapies Read more